Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility

[Image: see text] Following the approval of delamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed interest in bicyclic nitroimidazole scaffolds as a source of therapeutics against infectious diseases. We recently described a nitroimidazopyrazinone bicycli...

Descripción completa

Detalles Bibliográficos
Autores principales: Ang, Chee Wei, Tan, Lendl, Sykes, Melissa L., AbuGharbiyeh, Neda, Debnath, Anjan, Reid, Janet C., West, Nicholas P., Avery, Vicky M., Cooper, Matthew A., Blaskovich, Mark A. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770830/
https://www.ncbi.nlm.nih.gov/pubmed/33151678
http://dx.doi.org/10.1021/acs.jmedchem.0c01372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770830/
https://www.ncbi.nlm.nih.gov/pubmed/33151678
http://dx.doi.org/10.1021/acs.jmedchem.0c01372

Ejemplares similares